Spinraza in Adult Spinal Muscular Atrophy (SAS)
A Prospective, Multi-center, Observational Study of the Safety, Tolerability and Effectiveness of SPINRAZA® (Nusinersen) in Adult Patients With Spinal Muscular Atrophy
Sponsor: Washington University School of Medicine
Listed as NCT03709784, this observational or N/A phase trial focuses on Spinal Muscular Atrophy and Spinal Muscular Atrophy Type 3 and remains ongoing. Sponsored by Washington University School of Medicine, it has been updated 18 times since 2018, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
18 versions recorded-
Sep 2025 — Present [monthly]
Active Not Recruiting
-
Dec 2024 — Sep 2025 [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
-
Sep 2024 — Dec 2024 [monthly]
Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Recruiting
-
Dec 2023 — Jul 2024 [monthly]
Recruiting
Status: Active Not Recruiting → Recruiting
▶ Show 13 earlier versions
-
Sep 2022 — Dec 2023 [monthly]
Active Not Recruiting
-
Dec 2021 — Sep 2022 [monthly]
Active Not Recruiting
-
Sep 2021 — Dec 2021 [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
-
Jun 2021 — Sep 2021 [monthly]
Recruiting
-
Jan 2021 — Jun 2021 [monthly]
Recruiting
-
Nov 2020 — Jan 2021 [monthly]
Recruiting
-
Sep 2020 — Nov 2020 [monthly]
Recruiting
-
May 2020 — Sep 2020 [monthly]
Recruiting
-
Dec 2019 — May 2020 [monthly]
Recruiting
-
Nov 2019 — Dec 2019 [monthly]
Recruiting
-
Jun 2019 — Nov 2019 [monthly]
Recruiting
-
Jan 2019 — Jun 2019 [monthly]
Recruiting
-
Nov 2018 — Jan 2019 [monthly]
Recruiting
First recorded
Aug 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Washington University School of Medicine
For direct contact, visit the study record on ClinicalTrials.gov .